Epilepsy is a neurological (central nervous system) disorder which affects the brain activity, causing seizures or involuntary episodes of unusual behavior, shaking a part or complete body and sometimes loss of awareness. The epilepsy patient may experience commotion of consciousness and movements along with sensory or psychiatric disorders. Anyone can develop epilepsy, irrespective of gender, age, and race, and can cause other health ailments also. It is the fourth most common cause of neurological disorder across the world and on an estimate; there are nearly 24 million people suffering from epilepsy worldwide, creating immense opportunity for the research and development of anti-epileptic drugs.
According to a report published by Renub Research, Global Epilepsy Drugs Market is anticipated to be more than USD 9 Billion opportunity for pharmaceutical companies by 2025. This report talks about the upcoming Epilepsy Drugs Market its future potential and drugs going through its clinical trial phases. The report also provides insights on the key factors that are driving the market growth and challenges which are restraining the market growth.
People suffering from epilepsy may have more than one type of seizure and have other neurological disorder as well. Hence, to determine the treatment given, some of the common diagnostic tests for epilepsy patients include EEG (electroencephalogram) testing, family history, and clinical history. Epilepsy drugs (antiepileptic drugs) are medicines that are approved to treat epilepsy patients. Antiepileptic medicines (AEDs) are prescribed considering type and seriousness of seizure, the age of the patient and the part of the brain involved. Lyrica one of the leading antiepileptic brands, due to its efficacy, is widely recommended in treating epilepsy disorder. However, recently approved epilepsy drugs (Perampanel and Retigabine) are also driving the epilepsy drugs market as these drugs act through new molecular targets.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=epilepsy-drugs-market-p.php
Epilepsy drugs are generally termed as anti-seizure or anticonvulsants drugs which are used for the symptomatic treatment of epilepsy. Epilepsy drugs act as a mood stabilizers and so it is used in the treatment of bipolar disorder or neuropathic pain. Though the cause of epilepsy is unclear, some of the major factors causing epilepsy include brain tumor, brain injury, stroke, and substance use disorder. Changing lifestyle, smoking, alcoholism and growing geriatric population are among the leading factors that are driving the epilepsy drugs market.
In addition, owing to the approvals of new drugs for epilepsy further expected to boost the growth of epilepsy drugs market over the forecast period. On the other hand, recent patent expiration of major brands offers massive opportunity for the generic drugs to come up in the market. It is expected that due to the recent and in future patent expiration of major brands, the epilepsy drugs market would become very much competitive and the prices of branded drugs would come down, which is expected to hinder the growth of Epilepsy Drugs Market in the near future.
Client can Purchase this Report in Sections from below link:
Access full Research: https://www.renub.com/epilepsy-drugs-market-p.php
Market Summary:
• By Country: United States dominaties the epilepsy drugs market. US market share is expected to grow due to the better healthcare support system, growing awareness & increasing per capita healthcare expenditure. This report covers the market and market share of the United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan.
• Drugs Category – By Generation: Second and Third generation drugs are having a big market share. This research report provides market and market share of First, Second, Third generation drugs.
• By Drugs: Vimpat (Lacosamide) and Keppra (Levetiracetam) are holding big market share. Following drugs are covered in this report, Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex and Cenobamate (YKP3089).
• By Companies: The report provides overview, initiatives and financial insights of Eisai Co. Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc.
If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com
Browse Related Report:
Global Allergic Conjunctivitis Market
Contact Us
Renub Research
Phone:+1-678-302-0700
Email: info@renub.com
Key Topics Covered :
1. Executive Summary
2. Global Allergic Conjunctivitis Market and Patients Analysis
2.1 Allergic Conjunctivitis Market
2.2 Allergic Conjunctivitis Patient Numbers
2.3 Allergic Conjunctivitis Treated Patient Numbers
3. Share Analysis – Global Allergic Conjunctivitis
3.1 Country Market Share
3.2 Patients Population Share
3.3 Treated Patients Population Share
3.4 By Disease Type Share
4. India
4.1 Allergic Conjunctivitis Patient Numbers
4.2 Allergic Conjunctivitis Treated Patient Numbers
4.3 Allergic Conjunctivitis Market
5. China
5.1 Allergic Conjunctivitis Patient Numbers
5.2 Allergic Conjunctivitis Treated Patient Numbers
5.3 Allergic Conjunctivitis Market
6. Japan
6.1 Allergic Conjunctivitis Patient Numbers
6.2 Allergic Conjunctivitis Treated Patient Numbers
6.3 Allergic Conjunctivitis Market
7. United States
7.1 Allergic Conjunctivitis Patient Numbers
7.2 Allergic Conjunctivitis Treated Patient Numbers
7.3 Allergic Conjunctivitis Market
8. United Kingdom
8.1 Allergic Conjunctivitis Patient Numbers
8.2 Allergic Conjunctivitis Treated Patient Numbers
8.3 Allergic Conjunctivitis Market
9. France
9.1 Allergic Conjunctivitis Patient Numbers
9.2 Allergic Conjunctivitis Treated Patient Numbers
9.3 Allergic Conjunctivitis Market
10. Germany
10.1 Allergic Conjunctivitis Patient Numbers
10.2 Allergic Conjunctivitis Treated Patient Numbers
10.3 Allergic Conjunctivitis Market
11. Italy
11.1 Allergic Conjunctivitis Patient Numbers
11.2 Allergic Conjunctivitis Treated Patient Numbers
11.3 Allergic Conjunctivitis Market
12. Spain
12.1 Allergic Conjunctivitis Patient Numbers
12.2 Allergic Conjunctivitis Treated Patient Numbers
12.3 Allergic Conjunctivitis Market
13. Disease Type – Global Allergic Conjunctivitis Market
13.1 Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC)
13.2 Vernal Keratoconjunctivitis (VKC)
13.3 Atopic Keratoconjunctivitis (AKC)
13.4 Giant Papillary Conjunctivitis (GPC)
14. Global Allergic Conjunctivitis Drugs Profile/Pipe Line Drugs
14.1 Zerviate
14.2 OTX-DP (Dexamethasone Insert)
14.3 ADX-102
14.4 PRT2761
14.5 CVXL-0074
14.6 AK-002
14.7 Bertilimumab
14.8 Reproxalap
14.9 ST-266
14.10 SYL-116011
15. Growth Driver
15.1 Rapid Urbanization and Growth of Particulate Pollution
15.2 Increasing Ageing Population & Widespread Use of Medications for Various Eye Diseases
16. Challenges
16.1 Diagnostic Challenges
16.2 Undertreated by Patients
17. Santen Pharmaceutical
17.1 Company Overview
17.2 Initiatives
17.3 Financial Insight
18. Alcon Inc. (Novartis)
18.1 Company Overview
18.2 Initiatives
18.3 Financial Insight
19. Portola Pharmaceuticals Inc.
19.1 Company Overview
19.2 Initiatives
19.3 Financial Insight
20. Ocular Therapeutix Inc.
20.1 Company Overview
20.2 Initiatives
20.3 Financial Insight
About Us
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers andexecutives to make informed and correct decisions.
Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta
Email:Send Email
Phone: +1-678-302-0700
Address:225 Kristie Ln
City: Roswell
State: Georgia
Country: United States
Website: www.renub.com/drugs-and-pharmaceuticals-13-c.php
